Almirall SA (OTCPK:LBTSF)
$ 9.51 0.22 (2.37%) Market Cap: 2.25 Bil Enterprise Value: 2.31 Bil PE Ratio: 175.98 PB Ratio: 1.40 GF Score: 80/100

Almirall SA Lebrikizumab ADVocate 1 and 2 Call Transcript

Mar 30, 2022 / 02:00PM GMT
Release Date Price: $14.33
Pablo Divasson del Fraile
Almirall, S.A. - Head of IR & Corporate External Communication

Thank you, Nadia. Good afternoon to everyone on the call. Thank you for joining us on this call to review the 16-week data from lebrikizumab Phase III study. As usual, you can find the slides to this call on the Investors page of our website at almirall.com.

Moving to Slide 2. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. With that, please advance to Slide 3.

Presenting today, we have Gianfranco Nazzi, Chief Executive Officer; and Karl Ziegelbauer, Chief Scientific Officer. Gianfranco will start with a focus on the atopic dermatitis market. Karl will then provide you with detail on the atopic dermatitis, the IL-13 pathway and the 16-week Phase III of lebrikizumab. Gianfranco will then make the closing comments before opening up for a Q&A session.

I would like to pass you over to our CEO, Gianfranco Nazzi.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot